Glioblastoma (GBM) and brain metastases are lethal neoplastic disorders with limited treatment options and where pathogenesis is modulated by multiple cytokines. It is possible that cytokines released from glioblastoma or brain metastatic tissues, as well as from immune cells in the tumor microenvironment, can be non-invasively identified in the circulation. Identifying these biomarkers and developing unique molecular profiles of multiple interacting biomarkers in human plasma may have important utility in differentially diagnosing and staging both primary and secondary intracranial tumors, tracking disease progression, estimating prognoses, selecting optimal management strategies, and following treatment responses. Investigators today are challenged with choosing an assay that offers the highest sensitivity for cytokine detection and results in meaningful data. In this presentation, Dr. Diane Bender will describe a study which compared the performance of the MILLIPLEX® MAP Human High Sensitivity T Cell Magnetic Bead Panel with MSD V-Plex cytokine assay kits to quantify circulating cytokines in human plasma from brain cancer patients and healthy controls. The evaluation parameters included quantification limits, dynamic range, detection rate, and labor time to determine real-life performance for rapidly quantifying multiple cytokines in small-volume human plasma samples.